* AtriCure Inc ATRC.OQ ATRC.O is expected to show a rise
in
quarterly revenue when it reports results on February 21.
* The Mason Ohio-based company is expected to report a
19.7% increase in revenue to $87.657 million from $73.22 million
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data. The company's guidance on January 9
2023, for the period ended December 31, was for revenue of
$88.000 million.
* Refinitiv's mean analyst estimate for AtriCure Inc is for
a
loss of 18 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AtriCure
Inc is
$56.5, above its last closing price of $40.80.
The company's guidance on November 1 2022 for the period ended
December 31 was for Earnings before Interest, Taxes,
Depreciation and Amortization of of USD4 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.25 -0.25 -0.27 Missed -6.8
Jun. 30 2022 -0.29 -0.29 -0.32 Missed -9.3
Mar. 31 2022 -0.31 -0.32 -0.33 Missed -3.2
Dec. 31 2021 -0.29 -0.29 -0.30 Missed -3.4
Sep. -0.33 -0.32 2.11 Beat 750
30 2021
Jun. 30 2021 -0.34 -0.33 -0.36 Missed -7.5
Mar. 31 2021 -0.37 -0.37 -0.38 Missed -3.5
Dec. 31 2020 -0.27 -0.28 -0.28 Met 0.6
This summary was machine generated February 17 at 21:40 GMT.
All figures in US dollars unless otherwise stated